Healthcare
PDS Biotechnology Corporation(PDSB)
Live Price
Offline$0.9412
-1.45% today
1Y Change
-35.09%
Window
Jun 26, 2025 โ Jun 22, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +28.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 26, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PDS Biotechnology Corporation (PDSB) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $0.94 and down 35.1% across the available one-year price window (Jun 26, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +28.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +28.2%, free cash flow -79057.5% with operating margin 0.0% and ROIC -0.6%. Stock Foundry combines PDSB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +28.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +12.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +7.5% | -22.6% | -15.8% |
2026 Mar 30, 2026 | +30.0% | +12.7% | +70.9% | +101.1% |
2025 Nov 13, 2025 | +9.5% | -0.5% | -10.5% | +15.3% |
Benchmark Edge
PDSB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PDSB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PDSB Max Drawdown
-62.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PDSB and SPY.
Company Overview
PDS Biotechnology Corporation
NASDAQ Capital Market
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
- Leadership
- Frank K. Bedu-Addo
- IPO Date
- Sep 30, 2015
- Employees
- 24
- Street Address
- 25B Vreeland Road
- Mailing
- Princeton, NJ, 07932
- Region
- Princeton, NJ, US
- Reporting Currency
- USD
- Investor Line
- 800 208 3343
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.9
Growth
- Revenue
- 0.0%
- EPS
- +28.2%
- Free Cash Flow
- -79057.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -242.0%
- ROIC
- -0.6%
Balance Sheet
- Debt/Equity
- 561.21
- Current Ratio
- 2.82
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.